Skip to main content
Erschienen in: The European Journal of Health Economics 4/2005

01.12.2005 | Original Papers

Estimating utility data from clinical indicators for patients with stable angina

verfasst von: Louise Longworth, Martin J. Buxton, Mark Sculpher, David H. Smith

Erschienen in: The European Journal of Health Economics | Ausgabe 4/2005

Einloggen, um Zugang zu erhalten

Abstract

This study estimated a model from which data routinely collected in clinical trials of angina patients can be mapped to a utility scale and used to estimate quality-adjusted life years (QALYs). Patients with stable angina attending four cardiac out-patient clinics in the UK were included in the study. Data collected included information on patients’ health-related quality of life (HRQL) using the EQ-5D, and severity of angina symptoms using two cardiac-specific measures [Breathlessness Grade and Canadian Cardiovascular Society (CCS) classification of angina]. Regression analysis was used to predict EQ-5D index values from the data. Data were obtained from 510 patients. For CCS grades, mean EQ-5D scores ranged from 0.36 (95% confidence interval 0.25–0.48) for grade 4 to 0.81 (0.77–0.85) for grade 0, and for breathlessness grades, EQ-5D scores ranged from 0.31 (0.06–0.55) for grade 0 to 0.84 (0.79–0.88) for grade 5. The final model used data on CCS grades, breathlessness grades, and patients’ current medications to predict EQ-5D scores. The model had an R2 value of 0.37, and predictions for less severe angina were considered more reliable than the estimates for severe angina. In the absence of utility data collected as part of a clinical trial it is possible to map HRQL utility data from samples of patients with similar characteristics to those in the original trial. The uncertainty surrounding the estimates should be considered when using the results to estimate QALYs for purposes of economic evaluation.
Literatur
1.
Zurück zum Zitat Kind P (1996) The EuroQoL instrument: an index of health-related quality of life. In: Spilker B (1996) Quality of life and pharmacoeconomics in clinical trials. Lippincott-Raven, Philadelphia Kind P (1996) The EuroQoL instrument: an index of health-related quality of life. In: Spilker B (1996) Quality of life and pharmacoeconomics in clinical trials. Lippincott-Raven, Philadelphia
2.
Zurück zum Zitat Patrick DL, Erickson P (1993) Health status and health Policy. Allocating resources to health care. Oxford University Press, New York Patrick DL, Erickson P (1993) Health status and health Policy. Allocating resources to health care. Oxford University Press, New York
3.
Zurück zum Zitat Torrance GW, Feeny DH, Furlong WJ et al. (1996) Multiattribute utility function for a comprehensive health status classification system: Health Utilities Index Mark 2. Med Care 34:702–722CrossRefPubMed Torrance GW, Feeny DH, Furlong WJ et al. (1996) Multiattribute utility function for a comprehensive health status classification system: Health Utilities Index Mark 2. Med Care 34:702–722CrossRefPubMed
4.
Zurück zum Zitat Brazier J, Roberts J, Deverill M (2002) The estimation of a preference-based measure of health from the SF-36. J Health Econ 21:271–292CrossRefPubMed Brazier J, Roberts J, Deverill M (2002) The estimation of a preference-based measure of health from the SF-36. J Health Econ 21:271–292CrossRefPubMed
5.
Zurück zum Zitat Raftery J (2001) NICE: faster access to modern treatments? Analysis of guidance of health technologies. BMJ 323:1300–1303CrossRefPubMed Raftery J (2001) NICE: faster access to modern treatments? Analysis of guidance of health technologies. BMJ 323:1300–1303CrossRefPubMed
7.
Zurück zum Zitat Gold MR, Siegel JE, Russell LB et al. (1996) Cost-effectiveness in health and medicine. Oxford University Press: New York Gold MR, Siegel JE, Russell LB et al. (1996) Cost-effectiveness in health and medicine. Oxford University Press: New York
8.
Zurück zum Zitat Kinlay S (1996) Cost-effectiveness of coronary angioplasty versus medical treatment: the impact of cost-shifting. Aust N Z J Med 26:20–26PubMed Kinlay S (1996) Cost-effectiveness of coronary angioplasty versus medical treatment: the impact of cost-shifting. Aust N Z J Med 26:20–26PubMed
9.
Zurück zum Zitat Mark D, Harrington RA, Lincoff MA et al. (2000) Cost-effectiveness of platelet glycoprotein Iib/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation 101:366–371PubMed Mark D, Harrington RA, Lincoff MA et al. (2000) Cost-effectiveness of platelet glycoprotein Iib/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation 101:366–371PubMed
10.
Zurück zum Zitat Serruys PW, Unger F, Sousa JE et al. (2001) Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 344:1117–1124CrossRefPubMed Serruys PW, Unger F, Sousa JE et al. (2001) Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 344:1117–1124CrossRefPubMed
11.
Zurück zum Zitat Meslop KA, Boothroyd DB, Hlatky M (2003) Quality of life and time trade-off utility measures in patients with coronary artery disease. Am Heart J 145:36–41CrossRefPubMed Meslop KA, Boothroyd DB, Hlatky M (2003) Quality of life and time trade-off utility measures in patients with coronary artery disease. Am Heart J 145:36–41CrossRefPubMed
12.
Zurück zum Zitat RITA-2 Trial Participants (1997) Coronary angioplasty versus medical therapy for angina: the second randomised intervention treatment of angina (RITA-2) trial. Lancet 350:461–468CrossRefPubMed RITA-2 Trial Participants (1997) Coronary angioplasty versus medical therapy for angina: the second randomised intervention treatment of angina (RITA-2) trial. Lancet 350:461–468CrossRefPubMed
13.
Zurück zum Zitat Pocock SJ, Henderson RA, Clayton T et al. (2000) Quality of life after coronary angioplasty or continued medical treatment for angina: three year follow up in the RITA −2 trial. J Am Col Cardiol 34:907–914CrossRef Pocock SJ, Henderson RA, Clayton T et al. (2000) Quality of life after coronary angioplasty or continued medical treatment for angina: three year follow up in the RITA −2 trial. J Am Col Cardiol 34:907–914CrossRef
14.
Zurück zum Zitat Kirsch J, McGuire A (2000) establishing health state valuations for disease specific states: an example from heart disease. Health Econ 9:149–148CrossRefPubMed Kirsch J, McGuire A (2000) establishing health state valuations for disease specific states: an example from heart disease. Health Econ 9:149–148CrossRefPubMed
15.
Zurück zum Zitat Martin AJ, Glasziou PP, Simes RJ et al. (1998) Predicting patients’ utilities from quality of life items: an improved scoring system for the UBQ-H. Qual Life Res 7:703–711CrossRefPubMed Martin AJ, Glasziou PP, Simes RJ et al. (1998) Predicting patients’ utilities from quality of life items: an improved scoring system for the UBQ-H. Qual Life Res 7:703–711CrossRefPubMed
16.
Zurück zum Zitat Nichol G, Llewellyn-Thomas HA, Theil EC et al. (1996) The relationship between cardiac functional capacity and patient’ symptom-specific utilities for angina. Med Decis Making 16:78–85PubMed Nichol G, Llewellyn-Thomas HA, Theil EC et al. (1996) The relationship between cardiac functional capacity and patient’ symptom-specific utilities for angina. Med Decis Making 16:78–85PubMed
17.
Zurück zum Zitat Campeau L (1976) Grading of angina pectoris. Circulation 54:522–523 Campeau L (1976) Grading of angina pectoris. Circulation 54:522–523
19.
20.
Zurück zum Zitat Sculpher MJ, Seed P, Henderson RA et al. (1994) Health service costs of coronary angioplasty and coronary artery bypass surgery: the RITA trial. Lancet 344:927–930CrossRefPubMed Sculpher MJ, Seed P, Henderson RA et al. (1994) Health service costs of coronary angioplasty and coronary artery bypass surgery: the RITA trial. Lancet 344:927–930CrossRefPubMed
21.
Zurück zum Zitat Box GE, Cox D (1964) An analysis of transformations. J R Stat Soc Ser B 26:211–252 Box GE, Cox D (1964) An analysis of transformations. J R Stat Soc Ser B 26:211–252
22.
Zurück zum Zitat Dolan P, Gudex C, Kind P et al. (1996) The time trade-off method: results from a general population study. Health Econ 5:141–154CrossRefPubMed Dolan P, Gudex C, Kind P et al. (1996) The time trade-off method: results from a general population study. Health Econ 5:141–154CrossRefPubMed
23.
Zurück zum Zitat Briggs A, Clark T, Wolstenholme J et al. (2005) Missing...Presumed at random: cost-analysis of incomplete data. Health Econ 12:377–392CrossRef Briggs A, Clark T, Wolstenholme J et al. (2005) Missing...Presumed at random: cost-analysis of incomplete data. Health Econ 12:377–392CrossRef
24.
Zurück zum Zitat Nease RF Jr, Kneeland T, O’Connor GT et al. (1995) Variation in patient utilities for outcomes of the management of chronic stable angina. JAMA 273:1185–1190CrossRefPubMed Nease RF Jr, Kneeland T, O’Connor GT et al. (1995) Variation in patient utilities for outcomes of the management of chronic stable angina. JAMA 273:1185–1190CrossRefPubMed
Metadaten
Titel
Estimating utility data from clinical indicators for patients with stable angina
verfasst von
Louise Longworth
Martin J. Buxton
Mark Sculpher
David H. Smith
Publikationsdatum
01.12.2005
Verlag
Springer-Verlag
Erschienen in
The European Journal of Health Economics / Ausgabe 4/2005
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-005-0309-y

Weitere Artikel der Ausgabe 4/2005

The European Journal of Health Economics 4/2005 Zur Ausgabe